Uciane Scarlett is an Investment Principal at Science Business Builder Oxford Science Innovation. She holds a PhD in cancer immunology from Dartmouth College and specialises in life-sciences companies.
Between this and her previous role as Investor/Entrepreneur in Residence at US-based Atlas Venture, Uciane participated in the launch and growth of many companies.
She also operated within the cell & gene therapy companies Korro Bio and AVROBIO [Nasdaq: AVRO], where she supported/co-led operations and financing, scientific, and commercial strategies.
Having helped to raise Series A Rounds worth tens of millions of pounds, Uciane will share with you her knowledge of how VCs screen and filter proposals and how to make sure you get noticed.
Prior to joining Atlas, Uciane was the Director of BD & Strategy at Compass Therapeutics, a US-based clinical stage I-O/immunology company which launched in 2015 with a $132M Series A led by F-Prime & Orbimed.
Uciane currently represents OSI on the boards of T-Cypher, PepGen, MiroBio, Scenic Biotech, and DJS Antibodies and is building new companies in cell therapy, gene therapy, and neurosciences. She is also leading efforts on a pre-seed initiative which may launch in 2021, Pulsar.